EIA vaccine and diagnostic
AssigneeAkzo Nobel N.V.
InventorsRonald Montelaro, Bridget Puffer, Feng Li, Charles Issel, Kristina J. Hennessy, Karen K. Brown
Life of this patent
Estimating the term…
Abstract
The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.
Claims10
An immunogenic composition that produces an immune response from disease and/or infection caused by EIAV, said composition comprising a gene-mutated EIAV comprising two mutations, the two mutations comprising a mutation in the S2 accessory gene and a mutation in the DU gene wherein said virus lacks the ability to express the mutated gene or mutated genes protein in vivo and wherein said lack of expression can be used to differentiate vaccinated from non-vaccinated or infected mammals.
An immunogenic composition that produces an immune response from disease and/or infection caused by EIAV, said composition comprising a gene-mutated EIAV comprising two mutations, the two mutations comprising a mutation in the S2 accessory gene and a mutation in the DU gene wherein said virus lacks the ability to express the mutated gene or mutated genes protein in vivo.
Dependencies are inferred from the claim text.